Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2024-01-13

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel.

Zhang SM, Paulin CBJ, Shu H, Yagüe-Capilla M, Michel M, Marttila P, Ortis F, Bwanika HC, Dirks C, Venkatram RP, Wiita E, Jemth AS, Almlöf I, Loseva O, Hormann FM, Koolmeister T, Linde E, Lee S, Llona-Minguez S, Haraldsson M, Axelsson H, Strömberg K, Homan EJ, Scobie M, Lundbäck T, Helleday T, Rudd SG.

iScience · research-article; journal article · DOI 10.1016/j.isci.2024.108907

Bibliografisk träff 2013-04-09

Structure-based identification of OATP1B1/3 inhibitors.

De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.

Mol Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1124/mol.112.084152

Bibliografisk träff 2007-08-22

Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.

Ferrari AM, Degliesposti G, Sgobba M, Rastelli G.

Bioorg Med Chem · validation study; journal article · DOI 10.1016/j.bmc.2007.08.019

Bibliografisk träff 2000-03-01

Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.

Singh SB, Malamas MS, Hohman TC, Nilakantan R, Carper DA, Kitchen D.

J Med Chem · journal article · DOI 10.1021/jm990168z

Bibliografisk träff 1998-11-01

Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.

Fresneau P, Cussac M, Morand JM, Szymonski B, Tranqui D, Leclerc G.

J Med Chem · journal article · DOI 10.1021/jm9801399

Bibliografisk träff 1998-10-01

Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.

Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto J.

J Med Chem · journal article · DOI 10.1021/jm9802968

Bibliografisk träff 1994-03-01

Molecular modeling studies of aldose reductase inhibitors.

Lee YS, Pearlstein R, Kador PF.

J Med Chem · comparative study; journal article · DOI 10.1021/jm00032a011

Bibliografisk träff 1992-06-01

Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.

Lipinski CA, Aldinger CE, Beyer TA, Bordner J, Burdi DF, Bussolotti DL, Inskeep PB, Siegel TW.

J Med Chem · journal article · DOI 10.1021/jm00090a004

Bibliografisk träff 1991-11-01

Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.

DuPriest MT, Griffin BW, Kuzmich D, McNatt LG.

J Med Chem · journal article · DOI 10.1021/jm00115a011

Bibliografisk träff 1991-08-01

Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.

Wrobel J, Millen J, Sredy J, Dietrich A, Gorham BJ, Malamas M, Kelly JM, Bauman JG, Harrison MC, Jones LR.

J Med Chem · comparative study; journal article · DOI 10.1021/jm00112a029

Bibliografisk träff 1991-03-01

A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.

Mylari BL, Beyer TA, Siegel TW.

J Med Chem · comparative study; journal article · DOI 10.1021/jm00107a020

Bibliografisk träff 1991-01-01

Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.

Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH.

J Med Chem · comparative study; journal article · DOI 10.1021/jm00105a018